In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival.

Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany. florian.nolte@medma.uni-heidelberg.de

Leukemia research 2013 Apr

filter terms:

We evaluated the prognostic value of BAALC expression in 86 patients with acute promyelocytic leukemia (APL). At 10 years, the overall survival (OS) was 66% in all patients and 75% in patients who achieved a complete remission (CR). Patients in the BAALC(low) group showed an OS of 87% as compared to 60% in the BAALC(high) group (p=0.019). This difference was more pronounced in treatment responders (92% vs. 70%; p=0.035). In multivariate analyses low BAALC expression retained its prognostic relevance. In conclusion, BAALC expression analysis might be useful in further risk stratification in APL patients. Copyright © 2012 Elsevier Ltd. All rights reserved.

Citation

Florian Nolte, Anna Hecht, Mark Reinwald, Daniel Nowak, Verena Nowak, Benjamin Hanfstein, Andreas Faldum, Thomas Büchner, Karsten Spiekermann, Cristina Sauerland, Wolf-Karsten Hofmann, Eva Lengfelder. In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival. Leukemia research. 2013 Apr;37(4):378-82